28537-70-4

Usage

Uses

1. Used in Pharmaceutical and Biomedical Applications:
1,4-BIS-MALEIMIDOBUTANE is used as a crosslinking agent for the conjugation of proteins, peptides, and other biomolecules. Its application reason is to facilitate the formation of stable covalent bonds between the target molecules, enhancing their stability, and improving their performance in various biological processes.
2. Used in Chemical Synthesis:
1,4-BIS-MALEIMIDOBUTANE is used as a reagent in the synthesis of various chemical compounds, particularly those involving the formation of amide or peptide bonds. Its application reason is to provide a reliable and efficient method for the formation of these bonds, which are crucial in the development of new drugs, materials, and other chemical products.
3. Used in Research and Development:
1,4-BIS-MALEIMIDOBUTANE is used as a tool in research and development for studying the structure, function, and interactions of biomolecules. Its application reason is to enable researchers to investigate the properties of these molecules and develop a better understanding of their roles in biological systems.
4. Used in Quality Control and Diagnostics:
1,4-BIS-MALEIMIDOBUTANE is used as a component in the development of diagnostic tests and quality control assays. Its application reason is to provide a means for the detection and quantification of specific biomolecules, which can be crucial in the diagnosis and monitoring of various diseases and conditions.
5. Used in Material Science:
1,4-BIS-MALEIMIDOBUTANE is used as a crosslinking agent in the development of advanced materials, such as polymers and composites. Its application reason is to improve the mechanical, thermal, and chemical properties of these materials, making them more suitable for various industrial applications.

Upstream product

• 1449655-98-4 2,2'-(1,4-butanediyl)bis(3a,4,7,7a-tetrahydro-4,7-epoxy-1,3-bishydroisoindole-1,3-dione) 
• 55750-48-6 N-methoxycarbonylmaleimide 
• 110-60-1 1,4-diaminobutane 

Downstream Products

• 1373828-63-7 C₆₈H₄₈N₂O₈ 

Relevant academic research and scientific papers

An efficient reverse Diels-Alder approach for the synthesis of N-alkyl bismaleimides

Bismaleimides are useful precursors for Diels-Alder reactions, Michael additions, and thiol-maleimide based conjugation for the synthesis of materials and polymers. Use of bismaleimide cross linkers for generating polymers, bioconjugate molecules, and useful imaging molecules is an active area of research. An efficient and practical synthetic protocol for N-alkyl bis-maleimide cross linkers starting from furan protected maleimide employing a reverse Diels-Alder reaction is reported.

A New Class of Bradykinin Antagonists: Synthesis and in Vitro Activity of Bissuccinimidoalkane Peptide Dimers

A systematic study on the dimerization of the bradykinin (BK) antagonist D-Arg0-Arg1-Pro2-Hyp3-Gly4-Phe5-Ser6-D-Phe7-Leu8-Arg9 has been performed.The first part of this study involved compounds wherein dimerization was carried out by sequentially replacing each amino acid with cysteine and cross-linking with bismaleimidohexane.The second part of this study utilized a series of bissuccinimidoalkane dimers wherein the intervening methylene chain was varied systematically from n = 2 to n = 12 while the point of dimerization was held constant at position 6.The biological activities of these dimers were then evaluated on BK-induced smooth muscle contraction in two different isolated tissue preparations: guinea pig ileum (GPI) and rat uterus (RU).Several of the dimeric BK antagonists displayed remarkable activites and long durations of action.In addition, dimerization at position 4, 7, 8, or 9 produced dimeric analogues with markedly reduced potency.Rank order of antagonist potency as a function of dimerization position is as follows: rat uterus, 6 > 5 > 0 > 2 > 1 >3 >> 4, 7, 8, 9; guinea pig ileum, 6 > 5 > 3 > 2 > 1 > 0 >> 4, 7, 8, 9.Evaluation of the linker length as represented by the number of methylene units indicated an optimal distance between the two monomeric peptides of six to eight methylene moieties.These studies also revealed that the carbon-chain length significantly affected the duration of action in vitro and resulted in partial agonism effects when n > 8.The optimum activity in vitro was achieved with dimerization at position 6 and n = 6 (designated herein as compound 25; alternatively, CP-0127).Similar effects in potency were also seen when the monomeric antagonist D-Arg0-Arg1-Pro2-Hyp3-Gly4-Phe5-Ser6-D-Phe7-Phe8-Arg9 (NPC-567) was dimerized using similar chemistry.These results suggest that the development of BK antagonists of significant therapeutic potential may be possible using a dimerization strategy that can overcome the heretofore limiting problems of potency and in vivo duration of action found with many of the BK antagonists in the literature.